OBJECTIVE： To observe the clinical efficacy and safety of nedaplatin or cisplatin combined with paclitaxel plus chemoradiotherapy for middle-advanced uterine cervical cancer. METHODS： 120 patients with middle-advanced uterine cervical cancer were divided into observation group （60 cases） and control group （60 cases） by random. Observation group received nedaplatin 20 mg/m2 by intravenous infusion+paclitaxel 35 mg/m2 by intravenous infusion， once a week， control group received cisplatin 20 mg/m2 by intravenous infusion+paclitaxel 35 mg/m2 by intravenous infusion， once a week，2 groups also received radiation therapy first radiation therapy in whole pelvic by 1.8-2.0 Gy/times，once a day，5 times every week，then in pelvic outside by 1.8-2.0 Gy/times，once a day，4 times every week. And 2 groups were treated for 6 weeks. The short-term efficacy， 2-year survival rate， local control rate and the incidence of adverse reactions in 2 groups were observed. RESULTS： After treatment， the effective rate， 2-year survival rate and local control rate in observation group were significantly higher than control group， bone marrow suppression rate was significantly lower than control group， with statistical significance（P＜0.05）； there were no significant differences in the incidences of digestive tract reaction， liver and kidney function damage， hair loss， peripheral neuritis and other adverse reactions in 2 groups （P＞0.05）. CONCLUSIONS： Nedaplatin combined with paclitaxel plus chemoradiotherapy has good short-term efficacy， 2-year survival rate and local control rate for middle-advanced uterine cervical cancer than cisplatin combined with paclitaxel plus chemoradiotherapy， and little incidence of bone marrow suppression.